Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1Â Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
The FINE-HEART program aimed to evaluate the safety and efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), in key patient populations with type 2 diabetes, chronic kidney disease, and heart failure. By pooling data from three major Phase III trials—FINEARTS-HF, FIDELIO-DKD, and FIGARO-DKD—this comprehensive analysis sought to provide a clearer understanding of finerenone’s effects on cardiovascular mortality, renal outcomes, and hospitalizations for heart failure. The study also focused on subgroups based on diabetes control, offering valuable insights into its potential role in patients with coexisting conditions.
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1Â Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2Â In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1Â As of 2021, T2D ranked among the top causes of ...
Type 1 diabetes mellitus (T1DM) is an autoimmune disease secondary to the destruction of the insulin-producing β cells of the islets of the pancreas. Environmental factors presumably trigger the disease in genetically susceptible individuals, leading to a lifetime dependency on exogenous ...
Highlights Enhanced external counterpulsation (EECP) is evaluated for glycaemic control in type 2 diabetes. Glycated haemoglobin reduction immediately after EECP therapy conclusion, after 2–4 weeks and after 7–12 weeks was -0.70%, 1.04% and 0.98%, respectively. EECP is associated with a significant lowering of blood pressure. ...
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1Â For decades, glycated ...
Insulin remains an important diabetes treatment, with 150–200 million people worldwide requiring insulin therapy.1 While insulin is vital for managing type 1 diabetes, basal insulin is typically recommended for type 2 diabetes when non-insulin therapies are not enough to achieve glycaemic targets.2 Several ...
Type 2 diabetes mellitus (T2DM) is a severe public health issue notably impacting human life and health expenditure. Around 9.3% (463 million people) of the global population were living with diabetes in 2019, and this is projected to increase to 10.2% (578 million people) by 2030 ...
Worldwide prevalence of type 2 diabetes mellitus (T2DM) is steadily increasing due to rising levels of obesity over the past 40 years caused by sedentary lifestyles and unhealthy eating habits. Diabetes now ranks ninth among the top ten causes of death ...
Over 37 million people in the USA live with diabetes mellitus, equating to over 11% of the population.1 The large majority of these individuals (around 90–95%) have type 2 diabetes (T2D).1 Approximately 40% of patients T2D develop chronic kidney disease (CKD), with CKD ...
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide.1,2Â For this reason, early diagnosis and treatment are relevant to prevent the progression of this disease. Currently, the urinary albumin excretion ...
Nutrient-stimulated gastric inhibitory polypeptide (GIP) (known as either gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide) or glucagon-like peptide (GLP-1), are secreted by K and L cells, respectively, in the upper segment of the small intestine and throughout the intestine. For ...
For people with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), glycaemic control has been monitored by two key measurements: laboratory-tested glycated haemoglobin (HbA1c) level and the individuals’ self-monitored blood glucose (SMBG) fingerprick testing.1,2 Both of ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.